Vermont S 252: An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Status: Recommitted to Committee on Health and Welfare on motion of Senator Ashe (as of 2020-09-11)

State: Vermont · Session: 2019-2020 · Bill: S 252

Sponsors: Virginia Lyons

View Vermont S 252 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.